ProQR Therapeutics (PRQR) Common Equity (2012 - 2026)
ProQR Therapeutics (PRQR) posted Common Equity of $44.0 million for Q1 2026, down 23.41% sequentially from $57.5 million in Q4 2025, and down 46.99% YoY from $83.0 million in Q1 2025.
ProQR Therapeutics (PRQR) Common Equity (2012 - 2026) Analysis & Trends
ProQR Therapeutics has reported Common Equity for 15 years, with the latest figure at $44.0 million in Q1 2026.
- Quarterly Common Equity fell 46.99% year-over-year to $44.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.0 million (down 46.99% YoY) and the FY2025 annual result came in at $57.5 million, down 39.27% from the prior year.
- Common Equity eased to $44.0 million in Q1 2026 per PRQR's latest filing, from $57.5 million in the prior quarter.
- Over five years, Common Equity peaked at $113.8 million in Q1 2022 and troughed at $27.4 million in Q3 2024.
- A 5-year average of $63.7 million and a median of $63.0 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2025: Common Equity plunged 54.57% in 2022, then jumped 143.18% in 2025.
- Over 5 years, Common Equity stood at $68.0 million in 2022, then tumbled by 34.54% to $44.5 million in 2023, then surged by 112.5% to $94.6 million in 2024, then tumbled by 39.27% to $57.5 million in 2025, then declined by 23.41% to $44.0 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $44.0 million, $57.5 million, and $66.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | 44.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.02 Mn |
| Dec 31, 2025 | 57.47 Mn |
| Sep 30, 2025 | 66.72 Mn |
| Jun 30, 2025 | 75.82 Mn |
| Mar 31, 2025 | 83.03 Mn |
| Dec 31, 2024 | 94.63 Mn |
| Sep 30, 2024 | 27.44 Mn |
| Jun 30, 2024 | 35.38 Mn |
| Mar 31, 2024 | 37.83 Mn |
| Dec 31, 2023 | 44.53 Mn |
| Sep 30, 2023 | 50.45 Mn |
| Jun 30, 2023 | 56.08 Mn |
| Mar 31, 2023 | 63.01 Mn |
| Dec 31, 2022 | 68.03 Mn |
| Sep 30, 2022 | 68.58 Mn |
| Jun 30, 2022 | 95.37 Mn |
| Mar 31, 2022 | 113.84 Mn |
| Dec 31, 2021 | 130.54 Mn |
| Sep 30, 2021 | 150.97 Mn |
| Jun 30, 2021 | 141.55 Mn |